Immuneering (IMRX) traded down -2.1 % during a 24 hours period ending at 10:56 PM Central Europe on Monday 26th. One Immuneering stock can currently be bought for about USD 3.71 on popular exchanges. Current supply of Immuneering stocks is 64.7 mn. Immuneering has a current market capitalization of USD 241.3 mn and approximately USD 2.7 mn worth of Immuneering was traded on exchanges in the last 24 hours. Since last month end, Immuneering has traded -14.06 % down. Simple moving average of last 200 days is at USD 4.82. The highest price of past 52 weeks was recorded at USD 8.48 on 01/07/2026. 52 weeks low was at USD 3.38 on 10/15/2026.

Here is how related stocks have performed in the past 24 hours:

  • Build-a-bear Workshop (BBW) traded down -2.46 % and now trades at USD 23.78. Current market capitalisation for Build-a-bear Workshop is USD 287.3 mn. Current price/earnings ratio for Build-a-bear Workshop is 5.86.

  • Civeo (CVEO) traded up 2.57 % and now trades at USD 28.9. Civeo has a market capitalisation of USD 288.9 mn.

  • Opus Genetics (IRD) traded down -9.16 % and now trades at USD 3.32. Opus Genetics has a market capitalisation of USD 288.7 mn.

  • Inhibikase Therapeutics (IKT) traded down -2.45 % and now trades at USD 1.52. Current market capitalisation for Inhibikase Therapeutics is USD 289.5 mn.

  • Prelude Therapeutics (PRLD) traded up 0.83 % and now trades at USD 3.7. Prelude Therapeutics has a market capitalisation of USD 289.1 mn.

About Immuneering

Immuneering Corporation is a biopharmaceutical company operating in the health care sector with its base in Cambridge, United States. The company specializes in developing diagnostic platforms that harness human data, novel biology and chemistry, and translational planning to create new therapies for patients afflicted with debilitating oncologic and neurologic diseases. By focusing on these areas, Immuneering Corp. serves customers in the United States while utilizing their unique approach to disease detection and treatment. You can find more information about their work and offerings on their website, www.immuneering.com , or through trading on the Nasdaq stock exchange.